Annovis Bio, Inc. (ANVS)
About Annovis Bio, Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- -$28.9M
- Total assets
- $21.1M
- Market cap
- $80.4M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $29.7M
- Operating income
- -$29.7M
- Income tax
- $0
- Net income
- -$28.9M
- EPS (basic)
- $-1.40
- EPS (diluted)
- $-1.40
Balance sheet
- Total assets
- $21.1M
- Current assets
- $21.1M
- Total liabilities
- $4.2M
- Current liabilities
- $3.6M
- Shareholders’ equity
- $16.9M
Cash flow
- Operating cash flow
- -$25.6M
- Investing cash flow
- -$9.0M
- Financing cash flow
- $34.6M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $80.4M
- EPS (diluted)
- $-1.4
- Shares outstanding
- 48.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 29, 2020
Annovis Bio, Inc. (ANVS) Stock Price
- Reported a net loss of $28.9M in FY2025.
- Trading 67% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review Annovis Bio, Inc..
Write a review
News about Annovis Bio, Inc.
News & sentiment via Polygon.io
Annovis Bio, Inc.: frequently asked questions
Is Annovis Bio, Inc. an American company?
Annovis Bio, Inc. is a US-based company headquartered in Malvern, Pennsylvania, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Annovis Bio, Inc. headquartered?
Annovis Bio, Inc. is headquartered in Malvern, Pennsylvania, United States.
Is Annovis Bio, Inc. publicly traded?
Yes — Annovis Bio, Inc. is a publicly traded company. Its stock trades under the ticker symbol ANVS on the NYSE.
What does Annovis Bio, Inc. do?
Annovis Bio, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
